Browsing Tag
achondroplasia
5 posts
The drug that could dethrone Voxzogo: FDA clears Ascendis Pharma’s navepegritide alfa for achondroplasia
FDA approves Ascendis Pharma's navepegritide alfa for achondroplasia, intensifying competition with BioMarin's Voxzogo. Read what this means for the rare disease market.
Can Ascendis Pharma’s TransCon CNP still win FDA approval after the review extension?
FDA delays decision on Ascendis Pharma’s dwarfism drug TransCon CNP to February 2026 due to protocol revisions. See how this affects approval odds and launch.
BioMarin shares rise as new VOXZOGO and PALYNZIQ data reinforce market potential
Discover how BioMarin’s latest clinical data on VOXZOGO and PALYNZIQ at ACMG 2025 offers promising insights into rare disease treatments and what it means for the market.
FDA expands VOXZOGO approval for all ages with open growth plates
BioMarin Pharmaceutical Inc., a leading global biotechnology entity, unveiled that its drug, VOXZOGO (vosoritide), has received the green…
Pfizer wraps up $810m acquisition of Swiss biotech company Therachon
Pfizer acquisition of Therachon : US pharma giant Pfizer has completed its previously announced acquisition of Swiss biotech…